Related Experiment Video
Updated: Nov 7, 2025
Assaying the Kinase Activity of LRRK2 in vitro
Published on: January 18, 2012
In silico comparative analysis of LRRK2 interactomes from brain, kidney and lung
Amrita Verma1, Kirsten Ebanks1, Chi-Yee Fok1
1Reta Lila Weston Institute of Neurological Studies, Department of Clinical and Movement Neuroscience, UCL Queen Square Institute of Neurology, London WC1N 1PJ, United Kingdom.
Abstract:
Mutations in LRRK2 are the most frequent cause of familial Parkinson's disease (PD), with common LRRK2 non-coding variants also acting as risk factors for idiopathic PD. Currently, therapeutic agents targeting LRRK2 are undergoing advanced clinical trials in humans, however, it is important to understand the wider implications of LRRK2 targeted treatments given that LRRK2 is expressed in diverse tissues including the brain, kidney and lungs. This presents challenges to treatment in terms of effects on peripheral organ functioning, thus, protein interactors of LRRK2 could be targeted in lieu to optimize therapeutic effects. Herein an in-silico analysis of LRRK2 direct interactors in brain tissue from various brain regionswas conducted along with a comparative analysis of the LRRK2 interactome in the brain, kidney, and lung tissues. This was carried out based on curated protein-protein interaction (PPI) data from protein interaction databases such as HIPPIE, human gene/protein expression databases and Gene ontology (GO) enrichment analysis using Bingo. Seven targets (MAP2K6, MATK, MAPT, PAK6, SH3GL2, CDC42EP3 and CHGB) were found to be viable objectives for LRRK2 based investigations for PD that would have minimal impact on optimal functioning within peripheral organs. Specifically, MAPT, CHGB, PAK6, and SH3GL2 interacted with LRRK2 in the brain and kidney but not in lung tissue whilst LRRK2-MAP2K6 interacted only in the cerebellum and MATK-LRRK2 interaction was absent in kidney tissues. CDC42EP3 expression levels were low in brain tissues compared to kidney/lung. The results of this computational analysis suggest new avenues for experimental investigations towards LRRK2-targeted therapeutics.
Insights
Targeting Leucine-Rich Repeat Kinase 2 (LRRK2) is key for Parkinson's disease (PD) treatments. This study identified seven LRRK2 interactors in the brain for targeted PD therapy with minimal peripheral organ effects.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) are a primary cause of familial Parkinson's disease (PD).
- Common LRRK2 variants also increase idiopathic PD risk, prompting clinical trials for LRRK2-targeted therapies.
- LRRK2 expression in multiple organs necessitates understanding treatment implications for peripheral organ function.
Purpose of the Study:
- To identify potential therapeutic targets for Parkinson's disease by analyzing LRRK2 interactors.
- To compare the LRRK2 interactome across brain, kidney, and lung tissues to find targets with minimal peripheral effects.
- To guide the development of safer and more effective LRRK2-based Parkinson's disease treatments.
Main Methods:
- In-silico analysis of direct LRRK2 interactors in various brain regions.
- Comparative analysis of the LRRK2 interactome in brain, kidney, and lung tissues.
- Utilized protein-protein interaction (PPI) data, gene expression databases, and Gene Ontology (GO) enrichment analysis.
Main Results:
- Seven potential therapeutic targets (MAP2K6, MATK, MAPT, PAK6, SH3GL2, CDC42EP3, CHGB) for LRRK2-based PD investigations were identified.
- Specific interactions (e.g., MAPT, CHGB, PAK6, SH3GL2) were found in brain and kidney but not lung tissue.
- Differential expression patterns, such as low CDC42EP3 levels in the brain, suggest organ-specific targeting opportunities.
Conclusions:
- Identified seven viable targets for LRRK2-based Parkinson's disease investigations with potentially minimal impact on peripheral organs.
- The study provides a computational basis for prioritizing experimental research into novel LRRK2-targeted therapeutics.
- Findings suggest a refined approach to LRRK2-targeted drug development, considering tissue-specific interactions.
